Use of Monte Carlo Simulations to Select Therapeutic Doses and Provisional Breakpoints of BAL9141

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 5, 2004, Pages 1713-1718

  Mouton, Johan W ^a,d   Schmitt Hoffmann, Anne ^c   Shapiro, Stuart ^c   Nashed, Norman ^c   Punt, Nieko C ^b  

^a CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^b Medimatics   (Netherlands)

^c BASILEA PHARMACEUTICA INTERNATIONAL LTD   (Switzerland)

^d Wilhelmina Ziekenhuis   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CEFTOBIPROLE; CEPHALOSPORIN DERIVATIVE; PRODRUG; PYRROLIDINON 3 YLIDENEMETHYLCEPHALOSPORIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; COVARIANCE; DOSE RESPONSE; DRUG EFFICACY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NONHUMAN; PENICILLIN RESISTANCE; PRIORITY JOURNAL; SIMULATION; STRAIN DIFFERENCE; TARGET ATTAINMENT RATE;

ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; CEPHALOSPORINS; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, STATISTICAL; MONTE CARLO METHOD;

EID: 2142753041     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.5.1713-1718.2004     Document Type: Article

References (27)

1. Ambrose, P. G., and D. M. Grasela. 2000. The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae. Diagn. Microbiol. Infect. Dis. 38:151-157.
2. Ambrose, P. G., R. C. Owens, Jr., M. J. Garvey, and R. N. Jones. 2002. Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepime. J. Antimicrob. Chemother. 49:445-453.
3. Craig, W. A. 1998. Choosing an antibiotic on the basis of pharmacodynamics. Ear Nose Throat J. 77:7-11.
4. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-10.
5. Daum, R. S., and J. B. Seal. 2001. Evolving antimicrobial chemotherapy for Staphylococcus aureus infections: our backs to the wall. Crit. Care Med. 29:N92-N96.
6. Diekema, D. J., M. A. Pfaller, R. N. Jones, G. V. Doern, K. C. Kugler, M. L. Beach, H. S. Sader, and the SENTRY Participants Group. 2000. Trends in antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections in the USA, Canada and Latin America. Int. J. Antimicrob. Agents 13:257-271.
7. Diekema, D. J., M. A. Pfaller, F. J. Schmitz, J. Smayevsky, J. Bell, R. N. Jones, and M. Beach. 2001. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin. Infect. Dis. 32(Suppl. 2): S114-S132.
8. Drusano, G. L., S. L. Preston, M. H. Gotfried, L. H. Danziger, and K. A. Rodvold. 2002. Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob. Agents Chemother. 46:586-589.
9. Drusano, G. L., S. L. Preston, C. Hardalo, R. Hare, C. Banfield, D. Andes, O. Vesga, and W. A. Craig. 2001. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob. Agents Chemother. 45:13-22.
10. Dudley, M. N., and P. G. Ambrose. 2000. Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime time. Curr. Opin. Microbiol. 3:515-521.
11. Entenza, J. M., P. Hohl, I. Heinze-Krauss, M. P. Glauser, and P. Moreillon. 2002. BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis. Antimicrob. Agents Chemother. 46:171-177.
12. Fridkin, S. K. 2001. Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know. Clin. Infect. Dis. 32:108-115.
13. Hebeisen, P., I. Heinze-Krauss, P. Angehrn, P. Hohl, M. G. Page, and R. L. Then. 2001. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob. Agents Chemother. 45:825-836.
14. Jones, R. N., L. M. Deshpande, A. H. Mutnick, and D. J. Biedenbach. 2002. In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. J. Antimicrob. Chemother. 50:915-932.
15. Jones, R. N., C. M. Rubino, S. M. Bhavnani, and P. G. Ambrose. 2003. Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study Team. Antimicrob. Agents Chemother. 47:292-296.
16. Kahlmeter, G., D. F. J. Brown, F. W. Goldstein, A. P. MacGowan, J. W. Mouton, A. Österlund, A. Rodloff, M. Steinbakk, P. Urbaskova, and A. C. Vatopoulos. 2003. European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria. J. Antimicrob. Chemother. 52:145-158.
17. Kuti, J. L., C. H. Nightingale, R. Quintiliani, and D. P. Nicolau. 2002. Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis. Diagn. Microbiol. Infect. Dis. 44:51-57.
18. Leggett, J. E., S. Ebert, B. Fantin, and W. A. Craig. 1990. Comparative dose-effect relations at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis models. Scand. J. Infect. Dis. Suppl. 74:179-184.
19. Montgomery, M. J., P. M. Beringer, A. Aminimanizani, S. G. Louie, B. J. Shapiro, R. Jellife, and M. A. Gill. 2001. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. Antimicrob. Agents Chemother. 45:3468-3473.
20. Mouton, J. W. 2002. Breakpoints: current practice and future perspectives. Int. J. Antimicrob. Agents 19:323-331.
21. Mouton, J. W. 2003. Impact of pharmacodynamics on breakpoint selection for susceptibility testing. Infect. Dis. Clin. N. Am. 17:579-598.
22. Mouton, J. W., and N. Punt. 2001. Use of the t > MIC to choose between different dosing regimens of beta-lactam antibiotics. J. Antimicrob. Chemother. 47:500-501.
23. Mouton, J. W., M. L. van Ogtrop, D. Andes, and W. A. Craig. 1999. Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo. Antimicrob. Agents Chemother. 43:2473-2478.
24. National Nosocomial Infections Surveillance System. 2001. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992-June 2001, issued August 2001. Am. J. Infect. Control 29:404-421.
25. Nicolau, D. P., and P. G. Ambrose. 2001. Pharmacodynamic profiling of levofloxacin and gatifloxacin using Monte Carlo simulation for community-acquired isolates of Streptococcuspneumoniae. Am. J. Med. 111(Suppl. 9A): 13S-18S, 36S-38S.
26. Sanchez-Navarro, A., C. I. Colino, and M. M. Sanchez Recio. 2001. A retrospective analysis of pharmacokinetic-pharmacodynamic parameters as indicators of the clinical efficacy of ceftizoxime. Clin. Pharmacokinet. 40:125-134.
27. Schumitzky, A. 1991. Nonparametric EM algorithms for estimating prior distribution. Appl. Math. Comput. 45:141-157.